Lexeo Therapeutics Inc (NASDAQ:LXEO) shares, rose in value on Friday, June 20, with the stock price down by -7.78% to the previous day’s close as strong demand from buyers drove the stock to $3.91.
Actively observing the price movement in the last trading, the stock closed the session at $4.24, falling within a range of $3.64 and $4.2685. Referring to stock’s 52-week performance, its high was $19.50, and the low was $1.45. On the whole, LXEO has fluctuated by 10.76% over the past month.
With the market capitalization of Lexeo Therapeutics Inc currently standing at about $129.80 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LXEO’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of LXEO currently trading nearly 11.33% and 18.82% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 55.21, while the 7-day volatility ratio is showing 6.52% which for the 30-day chart, stands at 7.10%. Furthermore, Lexeo Therapeutics Inc (LXEO)’s beta value is 0.43, and its average true range (ATR) is 0.47.
A comparison of Lexeo Therapeutics Inc (LXEO) with its peers suggests the former has fared considerably weaker in the market. LXEO showed an intraday change of -7.78% in last session, and over the past year, it shrunk by -75.94%%.
Data on historical trading for Lexeo Therapeutics Inc (NASDAQ:LXEO) indicates that the trading volumes over the past 10 days have averaged 0.78 and over the past 3 months, they’ve averaged 1.02 million. According to company’s latest data on outstanding shares, there are 33.19 million shares outstanding.
Nearly 24.61% of Lexeo Therapeutics Inc’s shares belong to company insiders and institutional investors own 90.35% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.78 million shares as on 2025-05-30, resulting in a short ratio of 3.79. According to the data, the short interest in Lexeo Therapeutics Inc (LXEO) stood at 1328.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 3.26 million. The stock has fallen by -40.58% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LXEO stock heading into the next quarter.
